Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory skin condition that manifests as painful, deep-seated, inflamed nodules and abscesses in the axillary, groin, perianal, perineal, and inframammary regions. The associated pain, malodour, and disfigurement contribute to its profound negative impact on psychosocial spheres and overall quality of life in affected individuals. Although the symptoms of HS classically begin in the second or third decade of life, HS affects children and adolescents as well. Despite this, there are limited pediatric data on treatment, which are largely based on expert opinion, extrapolation of efficacy data in adults with HS, and safety information from medication use in other pediatric diseases. On this basis, there exist several pharmacological modalities in the treatment of children and adolescents with HS including topical therapies, systemic therapies, and biologics. The goals of this review article are to: (1) review the efficacy of different pharmacological treatment modalities in children and adolescents with HS, and (2) review the safety and monitoring considerations of the different treatment options in children and adolescents with HS.

化脓性汗腺炎 (HS) 是一种慢性、复发性炎症性皮肤病，表现为腋窝、腹股沟、肛周、会阴和乳房下区域出现疼痛、深部发炎的结节和脓肿。相关的疼痛、恶臭和毁容对受影响个体的心理社会领域和整体生活质量产生了深远的负面影响。虽然热射病的症状通常在二十岁或三十岁开始出现，但热射病也会影响儿童和青少年。尽管如此，有关治疗的儿科数据仍然有限，这些数据主要基于专家意见、成人热射病疗效数据的推断以及其他儿科疾病用药的安全性信息。在此基础上，治疗儿童和青少年热射病的药理学模式有多种，包括局部治疗、全身治疗和生物制剂。本文的目的是：(1) 回顾不同药物治疗方式对热射病儿童和青少年的疗效，(2) 回顾不同治疗方案对热射病儿童和青少年的安全性和监测注意事项。